Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

First In Human Study of CX-2051 in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06265688

Public ClinicalTrials.gov record NCT06265688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Study identification

NCT ID
NCT06265688
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
CytomX Therapeutics
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 1, 2024
Primary completion
Nov 29, 2027
Completion
Mar 30, 2029
Last update posted
Jul 14, 2026

2024 – 2029

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Sarah Cannon Research Institute at HealthONE Denver Colorado 80218 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02215 Recruiting
Montefiore Medical Center The Bronx New York 10461 Recruiting
Carolina BioOncology Institute, PLLC Huntersville North Carolina 28078 Recruiting
Sarah Cannon Research Institute, LLC Nashville Tennessee 37203 Recruiting
START - Dallas/Fort Worth Fort Worth Texas 76104 Recruiting
START San Antonio LLC San Antonio Texas 78229 Recruiting
NEXT Virginia Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06265688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06265688 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →